Biolegend, 109831, Brilliant Violet 421™ anti-mouse CD45.2 Antibody, 125microl

CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
125microl
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: B10.S mouse thymocytes and splenocytes
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For flow cytometric staining using the µl sizes , the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation4, in vivo and in vitro blocking of B cell responses1,2, and immunohistochemical staining of acetone-fixed frozen sections3.
Application References(PubMed link indicates BioLegend citation): Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block) Yakura H, et al. 1986. J. Immunol. 136:2729. (Block) Suzuki K, et al. 2000. Immunity 13:691. (IHC) Shen FW, et al. 1986. Immunogenetics 24:146. (IP) Baldwin TA and Hogquist KA. 2007. J. Immunol. 179:837. Pascal V, et al. 2007. J. Immunol. 179:1751. Burman AC, et al. 2007. Blood 110:1064. Kincaid EZ, et al. 2007. J. Immunol. 179:3187. Phan TG, et al. 2007. Nature Immunol. 8:992. Nakano-Yokomizo T, et al. 2011. J. Exp Med. 208:1661. PubMed Wen T, et al. 2013. PNAS. 110:6067. PubMed Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations: Nazet U, et al. 2021. Cells. 10:. PubMed Martin-Martin I, et al. 2022. Cell Rep. 39:110648. PubMed Corral D, et al. 2022. Cell Rep. 39:110715. PubMed Kemna J, et al. 2023. Nat Immunol. 24:414. PubMed Issa N, et al. 2023. Leukemia. :. PubMed Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed Pulous FE, et al. 2022. Nat Neurosci. 25:567. PubMed Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed Kinder JM, et al. 2020. Cell Reports. 31(12):107784.. PubMed Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed Christopher S Garris et al. 2018. Immunity. 49(6):1148-1161 . PubMed Juttukonda LJ, et al. 2017. Cell Host Microbe. 22:531. PubMed LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed Wilkinson AC, et al. 2020. Nature Protocols. 15(2):628-648.. PubMed Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed Wiesner D, et al. 2016. J Immunol. 196: 365 - 374. PubMed Garg G et al. 2019. Cell reports. 26(7):1854-1868 . PubMed Kim SP, et al. 2021. Cell Reports. 36(9):109626. PubMed Chopin M et al. 2018. Immunity. 50(1):77-90 . PubMed Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed Kawakami R, et al. 2021. Immunity. 54(5):947-961.e8. PubMed Yue X, et al. 2019. Nat Commun. 10:2011. PubMed Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed Crooks SD, et al. 2022. Immunohorizons. 6:705. PubMed Nazet U, et al. 2021. J Orofac Orthop. Online ahead of print. PubMed Lemaître F, et al. 2013. J Immunol. 191:1578. PubMed Van Braeckel-Budimir N, et al. 2018. Cell Rep. 24:3374. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Yang H, et al. 2019. J Neuroinflammation. 16:169. PubMed Zhang X, et al. 2022. JCI Insight. 7:. PubMed Severance AL, et al. 2022. iScience. 25:104400. PubMed Fukushima K, et al. 2020. Immunity. 52(3):542-556. PubMed Rosenbaum SR, et al. 2020. Cell Rep. 30:510. PubMed Engblom C, et al. 2017. Science. 358:6367. PubMed Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed Koide S, et al. 2022. iScience. 25:103603. PubMed Senatus L, et al. 2020. JCI Insight. 5:00. PubMed Knox T, et al. 2019. Sci Rep. 9:6136. PubMed Iwanami N, et al. 2020. iScience. 23:101260. PubMed Wilkinson AC, et al. 2019. Nature. 571:117. PubMed Allman W, et al. 2015. Proc Natl Acad Sci U S A. 112: 4094 - 4103. PubMed Tribble JR, et al. 2020. Mol Brain. 13:81. PubMed Song W, et al. 2022. Immunity. 55:290. PubMed Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
RRID: AB_10900256 (BioLegend Cat. No. 109831) AB_2565511 (BioLegend Cat. No. 109832)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family: CD Molecules
Antigen References: 1. Suzuki K, et al. 2000. Immunity 13:691.
Gene ID: 19264
UniProt: View information about CD45.2 on UniProt.org
Clone: 104
Regulatory Status: RUO
Other Names: Ly-5.2, LCA
Isotype: Mouse (SJL) IgG2a, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.